MeiraGTx Planning to Launch New Trial of AAV-GAD in Parkinson’s Patients

MeiraGTx Planning to Launch New Trial of AAV-GAD in Parkinson’s Patients
MeiraGTx is preparing to launch a new clinical trial of AAV-GAD, its investigational gene therapy for Parkinson’s disease. The company stated it is planning to file an investigational new drug (IND) application to obtain authorization to initiate the new trial testing the therapy in patients with Parkinson’s later this year or the beginning of 2021. AAV-GAD is an experimental gene ... read more
Source: Parkinson’s News TodayPublished on 2020-05-13By Joana Carvalho, PhD